The ROSALIND Tracker is a real-time dashboard for the United States rapid genotyping "Project ROSA" program for SARS-CoV-2. This research was supported by the National Institute of Biomedical Imaging and Bioengineering or the National Institutes of Health as part of the Rapid Acceleration of Diagnostics (RADxˢᵐ) initiative.
4 min read
Topics: Big Data Rosalind Public Data COVID-19
3 min read
OnRamp’s ROSALIND and Active Motif offer an improved ChIP-Seq data analysis experience for researchers with state-of-the-art dynamic track plots and advanced collaboration capabilities.
FOR IMMEDIATE RELEASE
San Diego, California – December 12, 2018 - OnRamp BioInformatics, a genomics company focused on scientist-friendly bioinformatics software solutions, today announced they are working with Active Motif to improve accuracies in data analysis for ChIP-Seq experiments.
OnRamp’s flagship software, ROSALIND, provides a point-and-click experience to speed up and simplify the process of genomic data analysis from experiment setup to QC and interactive data visualization to interpretation. With this integration, researchers will now benefit from an optimized analysis that includes the unique characteristics of Active Motif kits and antibodies, including Unique Molecular Identifiers (UMI) and spike-in solutions.
4 min read
OnRamp and Advaita announce a Strategic Partnership to bring collaboration and widespread accessibility to genomic data analysis
San Diego, CA – May 3, 2018 – OnRamp Bioinformatics, Inc., a genomics company providing the premier scientist-focused data analysis platform, and Advaita BioInformatics, a leader in personalized medicine and interpretation of Next-Gen Sequencing data, announced they are partnering to provide a comprehensive research experience from sample to interpretation with a seamless handoff between systems.
OnRamp.Bio’s flagship product, ROSALIND™, enables researchers, drug developers and bench scientists to analyze raw genomics data by providing a transformative experience through point-and-click experiment set up, interactive data visualization and interpretation. This new approach increases productivity by freeing up time for the bioinformatician to focus on more challenging workloads, while making bioinformatic analysis more accessible for the scientist to do more discovery with their data.
3 min read
Dr. Robi Ludwig interviews OnRamp CEO, Tim Wesselman, to explore the future needs for genomics to scale.
Tim Wesselman, the Chief Executive Officer of OnRamp.Bio, is on a mission to streamline, simplify and revolutionize the way we currently analyze and store genomic data, the data found within the DNA of every living thing.
You might be thinking, why is this so important? Well, this form of analysis allows researchers, biologists and drug developers to access the genomic information they need, which will permit them to achieve greater discoveries; discoveries that will benefit both individuals and society.
Wesselman spent the last two decades as a senior executive in top technology companies working on next generation data management and storage solutions (called hyper-scale). He is a graduate of multiple executive programs in Finance, Accounting, Investor Relations and Strategic Marketing from Columbia University, Rice University and University of Michigan and holds a B.S. Mechanical Engineering degree from Texas A&M University. Wesselman believes that software innovation will allow researchers to be in control of their own research, in a way that they aren’t now, enabling them to operate at a speed more in sync with today’s modern world’s pace: A pace which is becoming exponentially faster all of the time.
After a frightening experience Tim Wesselman had with the safety of his third unborn child who was medically at risk, he became even more determined to improve upon the research around this scientific quagmire when it came to obtaining genomic results for personalize medicine and patient care. The incident concerning his unborn child further underscored his belief that the inner secrets of life encoded in DNA, especially when it comes to disease and environment, are far too important to not be translated in a way that makes the most sense. In a way that facilitates the greatest minds of our time to find the answers, cures, and treatment impacting our current and future society.
Tim Wesselman and I got into more details about this intriguing and very modern scientific topic during our interview here.
1 min read
Our mission is to transform how cancer researchers and biologists analyze their data (at SCALE)!
Advanced bioinformaticians deserve all of the credit for building state-of-the-art applications to analyze genomic, proteomic, and microarray data. While these tools remain the lifeline of genomic analysis, more simplified user experiences are now required to empower today’s cancer biologists to focus on their research application, not which software application to use.
3 min read
Good News Bad News for Personalized Medicine.
I’m reminded daily of the many advancements towards personalized medicine, but one elephant remains firmly planted in the room.
Recently I came across an encouraging article that touched on the increasingly collaborative nature of the efforts to bring about this new age of personalized medicine. Data-sharing is reported to be on the rise in oncology, with groups like the Genomic Data Commons assembling harmonized genomic and clinical datasets, and making that information widely accessible to cancer researchers.
Topics: Big Data Personalized Medicine
2 min read
Challenges and opportunities in the research setting.
The emergence and mass utilization of high-throughput (HT) technologies, including sequencing technologies (genomics) and mass spectrometry (proteomics, metabolomics, lipids), has allowed geneticists, biologists, and biostatisticians to bridge the gap between genotype and phenotype on a massive scale. These new technologies have brought rapid advances in our understanding of cell biology, evolutionary history, microbial environments, and are increasingly providing new insights and applications towards clinical care and personalized medicine.